Literature DB >> 24712013

Do obstructive sleep apnea syndrome patients underestimate their daytime symptoms before continuous positive airway pressure treatment?

Gabrielle Leclerc, Yves Lacasse, Diane Page, Frédéric Sériès.   

Abstract

BACKGROUND: Daytime somnolence is an important feature of the obstructive sleep apnea (OSA) hypopnea syndrome and is usually subjectively assessed using the Epworth Sleepiness Scale (ESS).
OBJECTIVE: To compare the scores of the ESS and different domains of the Quebec Sleep Questionnaire (QSQ) assessed before and after the first months of continuous positive airway pressure (CPAP) treatment, as well as retrospectively without treatment.
METHODS: The ESS score and domain scores of the QSQ were obtained before and after a three-month period of CPAP treatment using a retrospective assessment of the pretreatment scores in 76 untreated OSA patients.
RESULTS: Fifty-two patients completed the study. The ESS and QSQ scores significantly improved following CPAP therapy. Retrospective evaluation of the ESS score was significantly worse than pre- and post-treatment values (mean [± SD] pretreatment score 11.0±4.8; retrospective pretreatment score 13.5±5.1). Such differences were not observed in any domain of the QSQ, including the domain assessing hypersomnolence.
CONCLUSION: OSA patients underestimated their sleepiness according to the most widely used instrument to assess hypersomnolence. This finding may not be observed with other methods used to assess OSA-related symptoms such as quality of life questionnaires.

Entities:  

Mesh:

Year:  2014        PMID: 24712013      PMCID: PMC4173888          DOI: 10.1155/2014/681952

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  24 in total

Review 1.  Obstructive sleep apnea and cardiovascular disease.

Authors:  Jo-Dee L Lattimore; David S Celermajer; Ian Wilcox
Journal:  J Am Coll Cardiol       Date:  2003-05-07       Impact factor: 24.094

2.  [Value of retrospective assessment of the Epworth Sleepiness Scale after long-term CPAP therapy in obstructive sleep apnea disorder]].

Authors:  C Zimmermann; D Köhler; B Schönhofer
Journal:  Pneumologie       Date:  2000-12

3.  Correlation of the Epworth Sleepiness Scale with respiratory sleep parameters in patients with sleep-related breathing disorders and upper airway pathology.

Authors:  Uta Bausmer; Haralampos Gouveris; Oxana Selivanova; Bjoern Goepel; Wolf Mann
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-06-19       Impact factor: 2.503

4.  Depressive symptoms and obesity as predictors of sleepiness and quality of life in patients with REM-related obstructive sleep apnea: cross-sectional analysis of a large clinical population.

Authors:  Sushmita Pamidi; Kristen L Knutson; Farbod Ghods; Babak Mokhlesi
Journal:  Sleep Med       Date:  2011-10-05       Impact factor: 3.492

5.  CPAP treatment in obstructive sleep apnoea: a randomised, controlled trial of follow-up with a focus on patient satisfaction.

Authors:  C Holmdahl; I-L Schöllin; M Alton; K Nilsson
Journal:  Sleep Med       Date:  2009-01-28       Impact factor: 3.492

6.  Factors influencing subjective sleepiness in patients with obstructive sleep apnea syndrome.

Authors:  Kenichi Hayashida; Yuichi Inoue; Shintaro Chiba; Tomoko Yagi; Mitsuyoshi Urashima; Yutaka Honda; Hiroshi Itoh
Journal:  Psychiatry Clin Neurosci       Date:  2007-10       Impact factor: 5.188

7.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

8.  A new standardised and self-administered quality of life questionnaire specific to obstructive sleep apnoea.

Authors:  Y Lacasse; M-P Bureau; F Sériès
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

9.  Response shift in perception of sleepiness in obstructive sleep apnea-hypopnea syndrome before and after treatment with nasal CPAP.

Authors:  Kazuo Chin; Shunichi Fukuhara; Kenichi Takahashi; Kensuke Sumi; Takaya Nakamura; Hisako Matsumoto; Akio Niimi; Noboru Hattori; Michiaki Mishima; Takashi Nakamura
Journal:  Sleep       Date:  2004-05-01       Impact factor: 5.849

10.  Metabolic syndrome, insulin resistance, fibrinogen, homocysteine, leptin, and C-reactive protein in obese patients with obstructive sleep apnea syndrome.

Authors:  Ozen K Basoglu; Fulden Sarac; Sefa Sarac; Hatice Uluer; Candeger Yilmaz
Journal:  Ann Thorac Med       Date:  2011-07       Impact factor: 2.219

View more
  5 in total

1.  Continuous positive airway pressure therapy in non-sleepy patients with obstructive sleep apnea: results of a meta-analysis.

Authors:  Dongmei Zhang; Jinmei Luo; Yixian Qiao; Yi Xiao
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

2.  The Quebec Sleep Questionnaire on quality of life in patients with obstructive sleep apnea: translation into Portuguese and cross-cultural adaptation for use in Brazil.

Authors:  José Tavares de Melo; Rosemeri Maurici; Michelle Gonçalves de Souza Tavares; Marcia Margareth Menezes Pizzichini; Emilio Pizzichini
Journal:  J Bras Pneumol       Date:  2017-07-31       Impact factor: 2.624

3.  Evaluation of an alternative care provider clinic for severe sleep-disordered breathing: a study protocol for a randomised controlled trial.

Authors:  Ada Ip-Buting; Jenny Kelly; Maria J Santana; Erika D Penz; W Ward Flemons; Willis H Tsai; Kristin L Fraser; Patrick J Hanly; Sachin R Pendharkar
Journal:  BMJ Open       Date:  2017-03-29       Impact factor: 2.692

4.  Pro: should asymptomatic patients with moderate-to-severe OSA be treated?

Authors:  Silke Ryan
Journal:  Breathe (Sheff)       Date:  2019-03

5.  Sleep disordered breathing from preschool to early adult age and its neurocognitive complications: A preliminary report.

Authors:  Kyriaki Astara; Dimitra Siachpazidou; George D Vavougios; Dimitrios Ragias; Konstantina Vatzia; Georgia Rapti; Emmanouil Alexopoulos; Konstantinos I Gourgoulianis; Georgia Xiromerisiou
Journal:  Sleep Sci       Date:  2021 Apr-Jun
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.